March 19, 2014

TRI's ND Infusion Catheter Approved in United States and European Union

April 29, 2014—The Translational Research Institute (TRI) announced that its ND infusion catheter has received US Food and Drug Administration clearance and European CE Mark approval for infusion of physician-specified fluids.

Used in both the coronary and peripheral vasculature, the ND infusion catheter is designed to isolate a specific vascular treatment region from blood flow during infusion while delivering the physician-specified fluid. The catheter's multilumen channels provide small luminal diameters. The ability of the micro channels to mix and disperse therapeutic agents potentially enhances efficacy, stated TRI.

According to the company, the ND infusion catheter improves patient safety and procedure outcome efficacy by reducing cellular clumping, improving dispersion, and reducing radial force. The device’s short balloon design accommodates different vessel diameters, potentially decreasing the chance of dissection. Additionally, the catheter’s balloon is designed to minimize pressure on the vessel wall during inflation.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

March 19, 2014

TRI's ND Infusion Catheter Approved in United States and European Union

Current Issue

Keep In Touch